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Purpose: Major depressive disorder (MDD) is highly prevalent in patients with a chronic 
physical condition, and this comorbidity has a negative influence on quality of life, health care 
costs, self-care, morbidity, and mortality. Research has shown that collaborative care (CC) may 
be a cost-effective treatment. However, its cost-effectiveness in this patient group has not yet 
been established. Therefore, the aim of this study was to evaluate the cost-utility of CC for the 
treatment of comorbid MDD in chronically ill patients in the outpatient general hospital setting. 
The study was conducted from a health care and societal perspective.
Patients and methods: In this randomized controlled trial, 81 patients with moderate-
to-severe MDD were included; 42 were randomly assigned to the CC group and 39 to the 
care as usual (CAU) group. We applied the TiC-P, short-form Health-Related Quality of 
Life questionnaire, and EuroQol EQ-5D 3 level version, measuring the use of health care, 
informal care, and household work, respectively, at baseline and at 3, 6, 9, and 12 months 
follow-up.
Results: The mean annual direct medical costs in the CC group were €6,718 (95% confidence 
interval [CI]: 3,541 to 10,680) compared to €4,582 (95% CI: 2,782 to 6,740) in the CAU group. 
The average quality-adjusted life years (QALYs) gained were 0.07 higher in the CC group, 
indicating that CC is more costly but also more effective than CAU. From a societal perspec-
tive, the incremental cost-effectiveness ratio was €24,690/QALY.
Conclusion: This first cost-utility analysis in chronically ill patients with comorbid MDD shows 
that CC may be a cost-effective treatment depending on willingness-to-pay levels. Nevertheless, 
the low utility scores emphasize the need for further research to improve the cost-effectiveness 
of CC in this highly prevalent and costly group of patients.
Keywords: collaborative care, randomized controlled trial, chronic physical condition, major 
depressive disorder, cost-utility, general hospital, CC–DIM
Plain language summary
The study was undertaken to establish if collaborative care (CC) is a cost-effective treatment 
model when provided in the general hospital outpatient setting, rather than the primary care 
setting, for patients with chronic physical conditions, such as diabetes mellitus (DM), chronic 
heart failure (CHF), and chronic obstructive pulmonary disease (COPD), with comorbid 
major depressive disorder (MDD). The researchers performed a randomized controlled trial 
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(RCT) evaluating CC provided by a consultant psychiatric nurse 
(CPN) as care manager; a consultation–liaison (CL) psychiatrist 
for diagnosis, supervision, and the prescription of antidepressant 
medication; and a medical specialist who provided treatment for 
the chronic physical condition. They found CC to be cost-effective 
with an incremental cost-effectiveness ratio (ICER) of €24,690 per 
quality-adjusted life year (QALY). Due to the high disease burden in 
this patient group, this may indicate that the CC model and setting 
may be preferable. However, the study was small, so replication in 
a larger study is warranted.
Introduction
Major depressive disorder (MDD) is deemed to become the 
leading cause of disability in 20301 and is a risk factor for 
a chronic physical condition.2 The prevalence of comor-
bid MDD in chronic physical conditions, such as chronic 
obstructive pulmonary disease (COPD), diabetes mellitus 
(DM), and congestive heart failure (CHF), is estimated to be 
between 7% and 16%.3 However, comorbid MDD often goes 
unrecognized in such cases as it may be difficult to distin-
guish these symptoms from the symptoms of the underlying 
medical condition.4
Comorbid MDD in chronic physical conditions is associ-
ated with maladaptive behavior, such as noncompliance with 
medical treatment recommendations. This is tripled in MDD,5 
with deterioration of general functioning, lower quality of 
life, and higher costs over the short and long terms.6 For 
example, DM patients with comorbid MDD report symptoms 
more frequently than DM patients with a similar severity of 
their chronic condition but without comorbid MDD, and this 
leads to increased medical testing and therefore higher costs.7 
In the case of DM and CHF, patients with comorbid MDD 
suffer greater health losses2,5 and have up to twofold higher 
medical costs compared to DM or CHF patients without 
comorbid MDD.8
It has been suggested that disease management inter-
ventions9 aimed at the treatment of MDD in patients with a 
chronic physical condition might increase the quality of life 
and decrease costs. In such programs, patients play an active 
role in their treatment and a care manager coordinates the treat-
ment in collaboration with other medical specialists. A spe-
cific form of disease management is collaborative care (CC), 
which has been proven to be effective in the USA, the UK, 
and the Netherlands,2,10–14 The findings of an efficacy study15,16 
showed that when CC was applied in the outpatient general 
hospital setting for chronic medically ill patients with comor-
bid MDD, there was no additional effect on the likelihood 
of remission and response compared to care as usual (CAU). 
However, it did significantly reduce the number of adverse 
medical events, which in turn may affect the quality of life. 
Since then, several systematic reviews have been undertaken 
exploring the effect of CC related to several chronic physi-
cal conditions, establishing its effect in terms of depressive 
symptoms over CAU. This has been found for cancer,17 
coronary heart disease,18 and DM.19–21
The efficacy of the model as a generic approach appli-
cable for a variety of chronic physical conditions and in the 
case of multimorbidity has also been explored in systematic 
reviews. A meta-analysis of individual participant data 
found CC to be effective against MDD in chronic physical 
conditions,22 and a systematic review found that CC is not 
only effective in reducing depressive symptoms, but also 
physical symptoms in chronic physical conditions with 
comorbid MDD.23
In terms of cost-effectiveness studies on CC for MDD, 
a review was published in 201024 showing that CC overall 
was more expensive, but increased the quality of life, with an 
incremental utility of between 0.03 and 0.12 quality-adjusted 
life years (QALYs). The studies in this review were mostly 
conducted in the USA and performed in a primary care 
setting. Another systematic review on studies in primary 
care found a dominance of CC over CAU.25 Since then, a 
randomized controlled trial (RCT) that explored the cost-
effectiveness of CC for MDD in primary care established its 
dominance over CAU.26–28 Another study in the occupational 
health setting found that CC did reduce costs, but also the 
effects in that setting.29–31 Only one study has investigated the 
cost-effectiveness of CC for patients with a chronic medical 
illness with comorbid MDD, namely DM. This study showed 
that CC was associated with a low increment in medical 
health care costs, while gaining high benefits.32
There is ongoing debate from the health services per-
spective concerning which setting is most fitting for CC of 
patients with comorbid MDD in chronic physical conditions: 
the primary care setting or the general hospital setting.33 Cost-
effectiveness may be one of the aspects taken into account in 
such a debate. However, so far, no cost-effectiveness studies 
regarding CC have been performed in the general hospital 
setting. This study aims to do so from a health care and a 
societal perspective.
The primary objective of this article is to assess the cost-
utility of CC for the treatment of comorbid MDD in chronic 
medically ill patients in the outpatient general hospital set-
ting from a societal perspective, taking all relevant costs and 
effects into account.
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Patients and methods
Design
A multicenter RCT was conducted from September 2007 to 
October 2010 in outpatient clinics for DM, COPD, inflam-
matory bowel disease (IBD), and chronic heart failure (CHF) 
in five general hospitals in the Netherlands in Amsterdam, 
Almelo, Hengelo, Ede, and Maastricht. The study consisted 
of a two-armed randomized controlled trial, with random-
ization at the patient level. Patients in the participating 
departments who screened positive on the patient health 
questionnaire-9 (PHQ-9) and had an MDD according to the 
mini international neuropsychiatric interview (MINI) were 
randomly allocated to the intervention group or the CAU 
group within their outpatient clinic by a blinded research 
assistant, using a computerized method to avoid assignment 
bias. The patients were not blinded for their group allocation. 
This method of randomization is often followed in psychiat-
ric intervention research.34 The intervention group received 
CC from a consultant psychiatric nurse (CPN), and in some 
cases antidepressant medication from the consultation–liaison 
(CL) psychiatrist in the department of Consultation–Liaison 
Psychiatry of the participating hospitals. The control group 
received CAU. The study protocol was approved by the 
Medical Ethics Committee (METC) of the VU University 
Medical Center and is described in greater detail elsewhere.15
study oversight
This RCT was part of the Depression Initiative, a national 
initiative to improve depression management in the 
Netherlands.35–37 A steering group, consisting of the principal 
investigator (CFC), and senior investigators involved in the 
design, management, and analysis of the trial (ATFB, LHR), 
monitored the progress in quarterly meetings to oversee 
the project.
Participants
During the inclusion period, all patients who had visited the 
participating outpatient departments in the previous year and 
had a confirmed chronic physical condition as specified in 
their medical records were selected from the medical files 
and were invited to participate by the nurses receiving them 
for their regular outpatient visits. The nurses handed them 
an envelope containing an information letter, an informed 
consent form, and the screening questionnaire (depression 
subscale of the PHQ-9) with a return envelope. Patients who 
consented and screened positive for depression then received 
the baseline questionnaire by mail. Patients who met the 
inclusion criteria based on the patient files but did not visit 
the participating departments received the same package by 
mail. In the information letter, the patients were asked if they 
were willing to participate in a study investigating mental 
problems and treatment options in the general hospital set-
ting. If they agreed to participate, they were asked to sign the 
informed consent form and return it together with the com-
pleted questionnaire to the researchers, who then contacted 
them to arrange to conduct the MINI.39
Inclusion criteria were the presence of a chronic physical 
condition, informed consent, age 18 years, and having a 
comorbid MDD as defined by a score of 10 on the PHQ-938 
and a positive MINI.39 Exclusion criteria were insufficient 
knowledge of the Dutch language, dementia or delirium, 
alcohol or drug addiction as a main diagnosis, psychotic or 
bipolar disorder, suicidality, and pregnancy.
intervention
In CC, treatment was provided by a team consisting of the 
patient, the CPN care manager, and the CL psychiatrist at 
the outpatient clinic of the general hospital according to an 
algorithm and monitored by a web-based tracking system 
that functioned as a supportive decision aid for the CPN care 
manager. Supervision and consultation by the CL psychiatrist 
was provided when the CPN care manager experienced 
difficulties in this process. The CC treatment encompassed 
guided self-help and problem-solving treatment (PST) 
provided by the CPN care manager in a one-to one session, 
antidepressants prescribed by the CL psychiatrist according 
to an algorithm, and consultations with the CL psychiatrist if 
necessary. According to the stepped care principle, treatment 
response was monitored biweekly with the PHQ-9. More 
details of the intervention are described elsewhere.15,16
care as usual
The control group patients received usual care in the general 
hospital setting, which consisted of a medical specialist 
monitoring their medical illness and advising the patient to 
seek treatment for their depressive symptoms from a primary 
care physician if they felt the need.15,16
Measures
Data collection was performed by the Trimbos Institute in 
cooperation with the participating hospitals. After providing 
informed consent, patients received assessment question-
naires by mail at baseline (T0), and after 3 months (T1), 
6 months (T2), 9 months (T3), and 12 months (T4).
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Quality of life
Quality of life was assessed with the EuroQol EQ-5D 3 
level version (EQ-5D-3L).40,41 This generic health index 
is a standardized, validated instrument that encompasses 
five dimensions: mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. Each dimension consists 
of three levels: no problems, some problems, and extreme 
problems. Therefore, it defines a total of 243 different health 
states. The mean utility scores were estimated by applying 
the area-under-the-curve (AUC) method, implemented by 
summing the areas of the geometrical shapes obtained by 
linearly interpolating between utility scores over the study 
period.42 Dutch tariffs were used to estimate utilities.
health care utilization costs
Part 1 of the treatment inventory cost in psychiatric patients 
(TiC-P) is a validated instrument that measures direct medical 
costs by estimating the number of contacts with health care 
services during the previous 3 months.42 We calculated the 
costs by multiplying the amount of care by the correspond-
ing reference unit prices from 2016 (indexed to unit prices 
from 2014).43 The direct costs estimated by the TiC-P were 
as follows: costs for the general practitioner (GP), mental 
health care institute, psychiatrist/psychologist at an outpatient 
center or hospital, occupational health care, medical special-
ist, paramedic care provider, social worker, consultation for 
alcohol/drugs, alternative treatment, self-help care, admis-
sion to part-time day care, (psychiatric) hospital admission, 
and medication. These costs were taken into account as they 
are part of the validated instrument. The CPN was the care 
manager in the CC group and was therefore important for our 
analysis. The unit price estimation was based on gross wages 
per year, working hours, session length of 1 hour, prepara-
tion of written reports, overheads, bonuses, and training. The 
amount of care provided by the CPN was recorded using a 
separate question about resource use. The indirect costs con-
sidered were household and informal costs. The inclusion of 
productivity costs related to paid work is especially relevant 
when the intervention is targeted at patients of working age. 
Due to the high age of the study population, we could reason-
ably expect cost-effectiveness outcomes to be unaffected by 
productivity costs, and therefore they could be ignored even 
when adopting a societal perspective.44 However, the costs 
of household work and informal care are considered highly 
relevant in this study population. We therefore included these 
costs outside health care.
In general, travel distances in the Netherlands are 
small, and consequently the costs are low. To avoid further 
increasing the numbers of questions asked of the patients, 
travel costs were not considered.
indirect costs
The second part of the TiC-P contains the short-form Health-
Related Quality of Life (SF-HLQ).45 This part assesses the 
amount of informal care and household work.
cost-utility
An incremental cost-effectiveness ratio (ICER) was calcu-
lated to obtain the costs per QALY, dividing the incremental 
costs by the incremental effects.
statistical analyses
Analyses were conducted using the Statistical Package 
for the Social Sciences (SPSS) version 19.0, R (version 
3.0.3.6), and Excel (2010). First, the direct costs and 
quality-of-life scores were calculated in SPSS. The cost-
effectiveness analysis was performed from a health care 
and a societal perspective. Uncertainty in the analysis was 
assessed using bootstrapping in R, with 5,000 iterations. 
Bootstrapping was conducted by drawing samples from 
the original sample (with replacement). For each of the 
bootstrapped samples, a generalized estimating equation 
model was applied for each outcome variable (ie, quality 
of life or costs). Costs were adjusted for the number of 
chronic conditions and age.46 Quality of life was adjusted 
for quality of life at baseline and age. We used a multi-
level model (generalized estimating equation) to adjust 
for imbalances between treatment arms and to allow for 
the correlation between measurements over time. By using 
this model, we could easily allow for correlation between 
measurements over time. We used a log link function with 
a gamma distribution for the costs and an identity function 
with a Gaussian distribution for quality of life. A correlation 
matrix with an autocorrelation structure was used for both 
costs and effects. In this way, 5,000 predicted incremental 
costs and 5,000 predicted incremental QALYs were gener-
ated. Each of the 5,000 ICERs was calculated as the mean 
of the predicted incremental costs divided by the mean of 
the incremental QALYs, expressed on a cost-effectiveness 
plane and a cost-acceptability curve. For this analysis, an 
“intention-to-treat” approach was used.
According to the Council for Public and Health Care 
(RVZ),47 the threshold in relation to the acceptability of the 
treatment depends on the severity of disease and uncertainty 
in the ICER, with a maximum of €80,000/QALY, and this is 
the decision rule that we applied in this study.
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Results
Population
A total of 11,330 patients were approached by mail or at the 
desk. Of these, 43% consented to screening. Reasons for lack 
of consent were inability to locate the patients because of a 
change of address, language problems, and among the persons 
approached at the desk, self-reported fatigue due to their chronic 
physical condition, which hampered collaboration. After the 
MINI and checking for exclusion criteria, 81 patients with mod-
erate-to-severe MDD could be randomized. Forty-two of these 
patients were randomly allocated to the CC group and 39 to the 
CAU group. Figure 1 provides a flowchart of the participants 
over the course of the study. Table 1 summarizes the baseline 
demographic and clinical characteristics for these patients. 
There were no significant differences in sociodemographic or 
clinical characteristics between the CC and CAU groups.
Dealing with missingness
Our analysis used a multilevel model. In this way, the 
skewness of the data, baseline corrections, and correlation 
between measurements over time could be taken into account. 
The advantage of a multilevel model (a generalized estimat-
ing equation model) is that the data are implicitly imputed 
by the model and the predictions of the model. The pattern of 
missingness in the data on quality of life and costs is shown in 
Table 2. Decisions on the variables in the model were made 
by plotting the residuals of the models and by using the quasi-
likelihood under the independence model criterion (QIC).
Quality of life
The utility scores for quality of life were calculated per 
measurement moment, as shown in Table 3. The mean 
utility scores at baseline were low in both the groups: 0.43 
(standard deviation [SD] =0.31) in the CC group and 0.45 
(SD =0.28) in the CAU group. The CC group improved 
significantly over time. In the CAU group, the utility values 
gained were 0.01 (95% confidence interval [CI]: –0.04 to 
0.05) and in the CC group 0.07 (95% CI: 0.02 to 0.13). The 
difference in effect was not significant over time: 0.07 (95% 
CI: –0.003 to 0.14).
Figure 1 Flowchart participants.
Note: T1: after 3 months, T2: 6 months, T3: 9 months, and T4: 12 months.
Abbreviations: caU, care as usual; cc, collaborative care; DsM-iV, Diagnostic and Statistical Manual of Mental Disorders – fourth edition; MiNi, mini international 
neuropsychiatric interview; PhQ-9, patient health questionnaire.
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Direct medical costs
The direct medical costs calculated per health care provider 
are shown in Table 4. The costs of the CPN (the care manager 
in the CC group) amounted to €291 in the CC group. The 
costs for the psychiatrist/psychologist were respectively 
€159 and €187 in the CC and CAU groups.
The percentage of patients who contacted the medical 
specialist or had a psychiatrist/psychologist consultation at 
an outpatient clinic was higher in the CC group compared to 
the CAU group. After applying the model and bootstrapping 
the data, the average costs per patient for the CC group were 
€6,490 (95% CI: 3,290 to 10,645) and the average costs per 
patient for the CAU group were €4,801 (95% CI: 2,878 to 
7,149), resulting in a difference of €1,689 (95% CI: –2,006 to 
5,974). The main costs are presented in the pie chart shown 
in Figure 2.
indirect costs
As shown in Table 5, the indirect costs for informal care and 
household work were, respectively, €189 (407) and €302 
(474) for the CC group. For the CAU group, these costs were 
€213 and €155.
health care perspective
The combination of higher direct medical costs and higher 
effects resulted in an ICER of €28,366/QALY, as shown in 
Table 6.
In Figure 3, the cost-effectiveness plane and the cost-
acceptability curve are shown. As can be seen, 80% of the 
ICERs fall into the north-east quadrant, indicating a com-
bination of higher effectiveness and higher direct medical 
costs for the CC group, and 17% of the ratios fall into the 
south-east quadrant, indicating that CC generates greater 
utilities and is less expensive compared to CAU.
At a threshold of €20,000/QALY, there is 40% probability 
that the intervention is accepted. At an ICER of €60,000/
QALY, there is ~80% probability that the intervention is 
accepted.
societal perspective
Again, there was a combination of higher direct medical 
costs and higher effect in the CC group, which resulted in 
Table 1 Baseline characteristics of the participants
Group Collaborative care  
(N=42)
Care as usual  
(N=39)
P-value
Male sex (%) 52.4 70.0 0.525
age, years (mean [sD]) 57 (11.6) 60 (11.6) 0.239
Dutch nationality (%) 95.2 90.0 0.522
Married or living with partner (%) 54.8 50.0 0.960
education beyond high school (%) 26.2 30.0 0.945
Number of chronic medical  
conditions (mean [sD])
4.2 (2.4) 4.4 (2.4) 0.747
severity of medical symptoms,  
lKV-checklist (mean [sD])
1.1 (0.4) 1.0 (0.5) 0.143
Paid job (%) 33.3 23.8 0.460
PhQ-9 score (mean [sD]) 16.6 (4.7) 16.5 (4.0) 0.974
Diabetes mellitus 40.5 35.9 0.415
cOPD 23.8 35.9
irritable bowel syndrome 0 2.6
congestive heart failure 35.7 25.6
Abbreviations: cOPD, chronic obstructive pulmonary disease; lKV, physical symptom checklist [lichamelijke Klachten Vragenlijst]; PhQ-9, patient health questionnaire; 
sD, standard deviation.
Table 2 Missing values in quality of life and cost data (N=81)
Percentage of complete data: 
quality of life (EQ-5D-3L)40,41
Percentage of complete 
data: costs (TiC-P)42
T0 100 96.3
T1 72.8 80.2
T2 64.2 61.7
T3 61.7 59.3
T4 59.3 55.6
Note: T0: baseline, T1: after 3 months, T2: 6 months, T3: 9 months, and T4: 
12 months. 
Abbreviations: eQ-5D-3l, euroQol eQ-5D 3 level version; Tic-P, treatment 
inventory cost in psychiatric patients.
Table 3 Mean utility scores40,41
Collaborative  
care (n=42)
Care as  
usual (n=39)
T0 0.43 (0.31) 0.45 (0.28)
T1 0.57 (0.30) 0.44 (0.28)
T2 0.51 (0.33) 0.50 (0.31)
T3 0.58 (0.32) 0.49 (0.30)
T4 0.54 (0.33) 0.50 (0.30)
Notes: T0: baseline, T1: after 3 months, T2: 6 months, T3: 9 months, and T4: 
12 months. Data presented as mean (sD). 
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cost-utility of collaborative care in the general hospital setting
an ICER of €24,690/QALY, as shown in Table 6. Although 
the indirect costs estimated were higher in the CC group, 
the model predicted otherwise, namely that the costs should 
actually be lower.
After bootstrapping, the ICERs were again plotted on 
a cost-effectiveness plane and a cost-acceptability curve 
(Figure 4). In this case, 77% of the ICERs fall into the north-
east quadrant of the cost-effectiveness plane, indicating that 
CC is associated with higher costs and also higher effects 
compared to CAU and 20% fall in the south-east quadrant, 
indicating higher costs and lower effects.
At a threshold of €20,000/QALY, there is ~60% probabil-
ity that the intervention is accepted. At an ICER of €60,000, 
there is ~80% probability that the intervention is accepted.
sensitivity analysis
A sensitivity analysis was performed from a societal perspec-
tive on admission to psychiatric hospital. These costs were 
relatively high in the CC group, but the number of contacts 
was relatively low. The costs for the CC group were now 
€4,287 (95% CI: 2,945 to 5,923) and the costs for the CAU 
group were €3,155 (95% CI: 2,378 to 4,034). The differ-
ence in costs was €1,132 (95% CI: -521 to 2,939). There 
was only a change in the incremental costs per QALY to 
€18,732/QALY. In addition, the majority of the cost–effect 
ratios (88%) still fall into the north-east quadrant and 10% 
into the south-east quadrant. The cost-effectiveness plane and 
the cost-acceptability curve are plotted in Figure 5.
Discussion
This study is the first cost-utility study of CC for the treat-
ment of comorbid MDD in patients with a chronic physical 
condition, namely DM, COPD, IBD, or CHF, in a general 
hospital outpatient setting. The higher costs and higher effects 
in the CC group lead to an ICER of €24,690/QALY from a 
societal perspective. We apply a decision rule of a maximum 
of €80,000/QALY, as explained earlier. The acceptability 
curve shows that at €20,000/QALY, there is a relatively low 
probability that the intervention is accepted. However, at a 
threshold of €60,000/QALY, the probability of acceptance 
increases to almost 80%. In this case, the ICER is €24,690/
QALY, which, in view of the significant disease burden of 
the patients, may be acceptable. When a health care perspec-
tive was considered, the ICER decreased to €18,732/QALY. 
A sensitivity analysis was conducted to investigate the effect 
of the costs of admission to a psychiatric hospital as these 
costs were relatively high, but the number of patients 
using them was relatively low. After the sensitivity analy-
sis, the ICER decreased and CC became more effective. T
ab
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The sensitivity analysis showed that the results are robust. This 
is a better outcome than the study on CC in MDD in the occu-
pational health setting, which found CC to be less costly but 
also less effective than CAU.31 It is also a better outcome than 
the study on CC in MDD in primary care, which found that, 
taking a health care perspective, CC was less cost-effective 
due to higher costs compared to CAU, which led to an ICER 
of €53,717/QALY. Hence, in terms of cost-effectiveness, CC 
may be particularly promising in patients with chronic physical 
conditions with comorbid MDD who receive treatment in the 
outpatient general hospital setting. According to the Council 
for Public and Health Care (RVZ), the threshold in relation 
to the acceptability of treatment depends on the severity of 
disease and uncertainty in the ICER, with a maximum of 
€80,000/QALY.47 According to this decision rule, an innova-
tive CC model based on the psychiatric consultation services 
of general hospitals may be a cost-effective intervention. 
However, replications of this research are necessary.
In both the groups, the largest part of the costs was due to 
hospital admissions for patients’ chronic physical conditions, 
which indicates the high disease burden in this patient group. 
Admission costs in the CC group were higher compared to 
the CAU group. However, these costs were due to a rela-
tively small group of patients, indicated by the large SD. 
Apart from that, the direct medical costs in the CC group 
were mainly caused by visits to a psychiatrist/psychologist at 
an outpatient center or hospital, the CPN care manager, and 
admission to part-time day care. This study was conducted 
from a societal perspective; however, the productivity costs 
were negligible as the age of the patients was high, and they 
were consequently in general no longer part of the working 
population. Furthermore, we did not have data on the utiliza-
tion of emergency care and therefore we could not estimate 
these costs. The same holds for medication for physical 
comorbid conditions. However, we do not expect these costs 
to be different between the two interventions. Hence, they are 
not expected to affect the ICER. With respect to occupational 
health care, we expect these costs not to be relevant due to 
the high age of the study population, meaning that they will 
generally be retired.
Figure 2 Pie charts presenting the percentage of costs of health care providers for the cc (left) and caU (right) groups.
Abbreviations: caU, care as usual; cc, collaborative care; gP, general practitioner.
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Table 5 costs per hour, number of hours, total costs, and number of missings for informal care and household work (euro’s 2016)
Costs per 
hour
Collaborative care (n=42) Care as usual (n=39)
Number of 
hours (SD)
Costs 
(SD)
Number  
of missings
Number of 
hours (SD)
Costs 
(SD)
Number  
of missings
informal care €14 13 (29) €189 (407) 12 15 (28) €213 (399) 6
household €23 13 (20) €302 (474) 15 7 (13) €155 (306) 12
Abbreviation: sD, standard deviation.
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Over time, the quality of life improved in both groups, 
but the quality of life in the CC group increased more 
(significantly). In the effect study,16 there was no signifi-
cant difference between the two groups in terms of total 
remission or of treatment response regarding depressive 
symptoms, as measured by the PHQ-9.38 However, the 
number of adverse events did significantly differ between 
the groups, decreasing more in the CC group, and this may 
subsequently have contributed to improved quality of life 
despite the continued presence of depressive symptoms. 
Further research is needed to explore the association 
between adverse effects, hospital admissions, and costs 
and quality of life in this patient group. The initial quality 
of life was low in both the CC and CAU groups, indicating 
that MDD in combination with a chronic disorder greatly 
affects quality of life. This finding corroborates the review 
of Simon,7 namely that additional impairment is experienced 
when depressive patients have a comorbid chronic physical 
condition. This study seems to show a weak trend toward 
increased quality of life in the CC group, contrary to the 
CAU group. However, the average quality of life is still 
remarkably low for both groups.
As CC was associated with higher costs and higher 
utilities, the results of this study agree with the findings 
of the review conducted by van Steenbergen-Weijenburg 
et al.24 The improvement in quality of life in CC was also 
substantiated in our study. Simon et al32 showed that after 
1 year, medical costs for CC in patients with comorbid 
Table 6 incremental costs and effects from health care and a societal perspective (euro’s 2016)
Collaborative care (n=42) Care as usual (n=39)
health care perspective
average direct medical costs €6,522 (95% ci: 3,239 to 10,760) €4,582 (95% ci: 2,782 to 6,740)
average utilities (QalY) 0.07 (95% ci: 0.02 to 0.13) 0.01 (95% ci: -0.04 to 0.05)
incremental costs €1,939 (95% ci: -1,751 to 6,428)
incremental utility 0.07 (95% ci: -0.002 to 0.14)
icer (euro/QalY) 28,366
societal perspective
average indirect costs €6,718 (95% ci: 3,541 to 10,680) €5,038 (95% ci: 3,159 to 7,346)
average utilities (QalY) 0.07 (0.02 to 0.13) 0.01 (-0.04 to 0.05)
incremental costs €1,680 (-1,951 to 5,911)
incremental utility 0.07 (95% ci: -0.002 to 0.14)
icer (euro/QalY) 24,690
Abbreviations: CI, confidence interval; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Figure 3 cost-effectiveness plane (left) and cost-acceptability curve (right) from a health care perspective.
Abbreviations: QalY, quality-adjusted life year; icer, incremental cost-effectiveness ratio.
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MDD in DM started to decline and at the end of the second 
year were lower than in CAU. This positive effect also 
extended to the benefits of intervention. This indicates 
that higher cost-effectiveness may be attained if a longer 
follow-up period is conducted, and this should be a topic 
for further research.
Research is warranted exploring how to lower the rela-
tively high costs found to be associated with CC for this 
patient group with a high disease burden. New developments, 
such as E-health and M-health interventions, have been 
suggested as alternatives for face-to-face psychotherapeutic 
treatments in this patient group; however, the expectations 
in terms of cost-effectiveness have as yet remained unful-
filled. Standalone E-health and M-health interventions in 
multimorbidity have been found to be associated with patient 
disengagement and physician withdrawal, and with low effec-
tiveness.48 Research attempts to develop cost-effective inter-
ventions for patients with multimorbidity should focus on 
patient safety,49 as a study of a tele-monitoring intervention 
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Figure 4 cost-effectiveness plane (left ) and cost-acceptability curve (right) from a societal perspective.
Abbreviations: QalY, quality-adjusted life year; icer, incremental cost-effectiveness ratio.
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Figure 5 sensitivity analysis; cost-effectiveness plane (left), and cost-acceptability curve (right) from a societal perspective.
Abbreviations: QalY, quality-adjusted life year; icer, incremental cost-effectiveness ratio.
to prevent hospitalization and emergency room visits pro-
vided evidence of higher mortality compared to CAU in 
elderly patients with multimorbidity.50 The outcomes of our 
study, showing somewhat more hospital admissions in the 
CC group, might be related to better monitoring of adverse 
somatic developments in the CC intervention requiring 
admission, thus resulting in better quality of life. Hence, 
also in terms of safety, in this patient group with chronic 
physical conditions, CC may be the model of choice despite 
the higher costs. However, this should be explored in further 
research. Further research might also evaluate a combination 
of CC and E-health, or tele-monitoring in so-called blended 
E-health models, in which clinical diagnostic and treat-
ment evaluation is strongly embedded. Thus, no physician 
withdrawal or patient disengagement should occur. Such 
treatment should focus not only on the treatment of MDD, 
but also on better management and quality of life regarding 
the chronic physical condition at hand, and should also take 
mortality as an outcome into account.51
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limitations of the study
The first limitation of this study was the small sample size. 
Based on the prevalence rates indicated in the literature, this 
study was originally set up as a clinical trial in one hospital, 
but due to low inclusion rates, it was extended to a multicenter 
trial, thus providing sufficient participants to perform the 
study. Although initially response to the mail invitation was 
43%, low inclusion rates were caused by patients having 
lower comorbid MDD rates than initially expected based on 
the literature; as can be seen from the flowchart, the actual 
number of patients fulfilling the MINI classification for 
MDD was only 169, of whom a further 88 had to be excluded 
because of acute suicidality, psychosis, addiction, and 
dementia, inter alia. This warrants further research into the 
prevalence of comorbid MDD in chronic physical conditions 
in clinical cohort studies. Another reason for the low inclusion 
rates was that patients felt too ill to participate in the study, 
particularly as their chronic physical condition necessitated 
focusing on that alone. A further limitation of the study was 
the high dropout rate,26 which was to be expected given the 
high burden of illness due to the combination of psychological 
and physical complaints in this patient group. This illustrates 
one of the reasons why few studies have yet been performed 
in this setting and with this population.
Conclusion
This first study has demonstrated the cost-utility of CC com-
pared to CAU in an outpatient general hospital setting using 
a relatively long perspective. Despite the small patient group, 
it was possible to establish some clear findings on the quality 
of life and costs among outpatients with chronic physical 
conditions and comorbid MDD. According to the Council 
for Public and Health Care (RVZ), the threshold in relation 
to the acceptability of treatment depends on the severity of 
disease and uncertainty in the ICER, with a maximum of 
€80,000/QALY. According to this decision rule, an innova-
tive CC model based on the psychiatric consultation services 
of general hospitals may be a cost-effective intervention. 
However, replications of this research are necessary.
This study showed incremental quality-of-life gains in 
applying a CC model for this patient group. Nevertheless, 
the low utility scores emphasize the need for further research 
to improve the (cost-)effectiveness of CC in this highly 
prevalent and costly group of patients.
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